Standout Papers

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2019 2026 2021 2023 444
  1. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019)
    Laurie H. Sehn, Alex F. Herrera et al. Journal of Clinical Oncology
  2. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022)
    Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology

Immediate Impact

7 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
27 intermediate papers

Works of Matthew J. Matasar being referenced

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 Standout
Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era
2016
and 18 more

Author Peers

Author Last Decade Papers Cites
Matthew J. Matasar 2535 2271 873 180 3.7k
Paul A. Hamlin 2783 1998 891 153 3.8k
Chan Y. Cheah 2178 1608 1159 190 3.3k
Jehan Dupuis 3026 1711 884 114 4.0k
John Sweetenham 2698 2002 1446 138 4.5k
Karim Belhadj 2299 1588 760 97 3.5k
Christophe Fermé 3565 2370 1177 97 4.2k
Luigi Rigacci 3011 1537 780 138 3.9k
Marcel Reiser 2439 1856 1260 124 3.5k
Catherine Sebban 2265 1786 839 68 3.0k
Francesco Merli 3320 1782 846 156 4.2k

All Works

Loading papers...

Rankless by CCL
2026